VolitionRX’s (VNRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $3.00 target price on the medical research company’s stock.

Separately, Maxim Group cut VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, VolitionRX currently has an average rating of “Buy” and a consensus target price of $2.50.

VolitionRX Stock Performance

Shares of VolitionRX stock opened at $0.20 on Thursday. The stock has a market capitalization of $26.65 million, a P/E ratio of -0.85 and a beta of 1.33. VolitionRX has a 52-week low of $0.17 and a 52-week high of $0.94. The stock’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.34.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Silverberg Bernstein Capital Management LLC grew its position in shares of VolitionRX by 15.6% during the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 31,300 shares in the last quarter. Virtu Financial LLC bought a new stake in VolitionRX during the third quarter valued at $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRX during the second quarter valued at $52,000. Geode Capital Management LLC grew its position in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in VolitionRX during the fourth quarter worth about $28,000. 8.09% of the stock is owned by institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.